Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Gianni, T. Pieńkowski, Y. Im, L. Roman, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.The Lancet. Oncology, 13 1
N. Harbeck, O. Gluz, M. Christgen, M. Braun, Sherko Kummel, J. Potenberg, B. Aktas, C. Schumacher, H. Forstbauer, D. Augustin, Stefan Kraemer, M. Just, J. Tio, A. Kleine-Tebbe, C. Liedtke, R. Kates, D. Hofmann, R. Wuerstlein, H. Kreipe, U. Nitz (2015)
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.Journal of Clinical Oncology, 33
P. Mcgale, Carolyn Taylor, C. Correa, D. Cutter, F. Duane, Marianne Ewertz, Richard Gray, G. Mannu, R. Peto, Tim Whelan, Y. Wang, Zhe Wang, Sarah Darby (2014)
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trialsLancet (London, England), 383
I. Krop, Sung-Bae Kim, A. González-Martín, P. LoRusso, J. Ferrero, M. Smitt, R. Yu, A. Leung, H. Wildiers (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.The Lancet. Oncology, 15 7
P. Ellis, C. Barrios, W. Eiermann, M. Toi, Y. Im, P. Conte, Miguel Martín, T. Pieńkowski, X. Pivot, H. Burris, A. Strasak, M. Patre, E. Perez (2015)
Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.Journal of Clinical Oncology, 33
R. Finn, J. Crown, I. Láng, K. Boér, I. Bondarenko, Sergey Kulyk, J. Ettl, Ravi Patel, T. Pintér, Marcus Schmidt, Y. Shparyk, A. Thummala, N. Voytko, C. Fowst, Xin Huang, Sindy Kim, S. Randolph, D. Slamon (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.The Lancet. Oncology, 16 1
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael Lu, S. Olsen, K. Blackwell (2012)
Trastuzumab emtansine for HER2-positive advanced breast cancer.The New England journal of medicine, 367 19
E. Nichols, M. Piccart-Gebhart (2013)
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab after Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up, 12
M. Gnant, B. Mlineritsch, G. Luschin-Ebengreuth, F. Kainberger, H. Kässmann, J. Piswanger-Sölkner, M. Seifert, F. Ploner, C. Menzel, P. Dubsky, F. Fitzal, V. Bjelic-Radisic, G. Steger, R. Greil, C. Marth, E. Kubista, H. Samonigg, P. Wohlmuth, M. Mittlböck, R. Jakesz (2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.The Lancet. Oncology, 9 9
S. Hurvitz, L. Dirix, J. Kocsis, G. Bianchi, Janice Lu, J. Vinholes, E. Guardino, Chunyan Song, B. Tong, V. Ng, Y. Chu, E. Perez (2013)
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 9
J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott, E. Clark, M. Benyunes, G. Ross, S. Swain (2012)
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.The New England journal of medicine, 366 2
A. Goldhirsch, M. Piccart-Gebhart, M. Procter, E. Azambuja, H. Weber, M. Untch, I. Smith, L. Gianni, C. Jackisch, D. Cameron, R. Bell, M. Dowsett, R. Gelber, B. Leyland-Jones, J. Baselga (2012)
Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow upCancer Research, 72
J. Ro, F. André, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, C. Bartlett, Ke Zhang, C. Giorgetti, S. Randolph, M. Koehler, M. Cristofanilli (2015)
PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18_suppl
J. Bergh, K. Pritchard, K. Albain, S. Anderson, R. Arriagada, W. Barlow, W. Bergsten-Nordström, J. Bliss, F. Boccardo, R. Bradley, M. Buyse, D. Cameron, M. Clarke, M. Coates, R. Coleman, C. Correa, J. Costantino, J. Cuzick, N. Davidson, C. Davies, A. Leo, M. Dowsett, M. Ewertz, J. Forbes, R. Gelber, R. Geyer, R. Gianni, M. Gnant, A. Goldhirsch, R. Gray, D. Hayes, C. Hill, J. Ingle, W. Janni, E. Mackinnon, M. Martin, P. Mcgale, L. Norton, Y. Ohashi, S. Paik, H. Pan, E. Perez, R. Peto, R. Piccart, L. Pierce, V. Raina, P. Ravdin, J. Robertson, E. Rutgers, J. Sparano, S. Swain, Carolyn Taylor, G. Viale, G. Minckwitz, Xiang Wang, T. Whelan, N. Wilcken, E. Winer, N. Wolmark, W. Wood (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsThe Lancet, 386
M. Gnant, G. Pfeiler, P. Dubsky, M. Hubalek, R. Greil, R. Jakesz, V. Wette, M. Balić, F. Haslbauer, Elisabeth Melbinger, V. Bjelic-Radisic, S. Artner-Matuschek, F. Fitzal, C. Marth, P. Sevelda, B. Mlineritsch, G. Steger, Diether Manfreda, R. Exner, D. Egle, J. Bergh, F. Kainberger, S. Talbot, D. Warner, C. Fesl, C. Singer (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialThe Lancet, 386
L. Gianni, T. Pieńkowski, Y. Im, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, Giulia Bianchi, Virginia McNally, Hannah Douthwaite, G. Ross, P. Valagussa (2015)
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).Journal of Clinical Oncology, 33
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
A. Chan, S. Delaloge, F. Holmes, B. Moy, H. Iwata, Vernon Harvey, Nicholas Robert, T. Silovski, E. Gokmen, G. Minckwitz, B. Ejlertsen, S. Chia, Janine Mansi, Carlos Barrios, M. Gnant, A. Wong, R. Bryce, B. Yao, Miguel Martín (2015)
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).Journal of Clinical Oncology, 33
Several important studies were presented at the 2015 ASCO Annual Meeting in the field of breast cancer. Austrian Breast and Colorectal Study Group trial 18 again indicated the importance of bone health in postmenopausal women receiving endocrine therapy and showed that denosumab, a monoclonal antibody targeting the RANK ligand, was highly active in the reduction of fracture rates in this population. In the metastatic setting, addition of palbociclib to fulvestrant nearly tripled progression-free survival in pretreated women with luminal breast cancer as shown in the randomized phase III PALOMA-3 trial. In HER2-positive breast cancer, results from a randomized phase II study suggested that T-DM1 with or without endocrine therapy may be a valuable option as neoadjuvant treatment. In this trial, pathologic complete remission rates of > 40 % were observed after only four cycles of T-DM1. The phase III ExteNET study evaluated the role of neratinib, a tyrosine-kinase inhibitor targeting HER2 and epidermal growth factor receptor, as extended adjuvant therapy after 1 year of trastuzumab; while the future role of neratinib remains still undefined, this was the first study to show an improvement in terms of disease-free survival over the current treatment standard. Finally, the MARIANNE trial showed that T-DM1 was as effective as trastuzumab plus docetaxel as first-line therapy, while dual HER2-inhibition with T-DM1 plus pertuzumab yielded no further benefit.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Nov 3, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.